top of page



Genevoyager provides one-stop gene therapy solutions. With a novel approach to regulating expression cassettes, Genevoyager developed a proprietary One-Bac 4.0 system for large-scale adeno-associated virus (AAV) production. This results in high yields, enhanced infectivity, and higher full/empty capsid ratios. Our end-to-end services cover the entire drug life cycle, from designing and screening drug candidates at the preclinical stage through commercial manufacturing. Genevoyager stands committed to delivering safe, effective, and accessible AAV gene therapy solutions.

BrainVTA, one of our subsidiaries, has been delivering various viral vectors and customized services since 2014. To date, we have served more than 200 clients across the world.

We are backed by a team of 300+ highly skilled professionals with a proven track record in viral vector research and development, preclinical studies, CMC development, QA/QC, and GMP production.

bottom of page